Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Immuneering (IMRX) EBITDA Margin (2020 - 2022)

Immuneering's EBITDA Margin history spans 3 years, with the latest figure at 2886419.34% for Q4 2022.

  • On a quarterly basis, EBITDA Margin fell 288070777.0% to 2886419.34% in Q4 2022 year-over-year; TTM through Sep 2023 was 11315518.9%, a 1130599682.0% decrease, with the full-year FY2022 number at 15931.33%, down 1431665.0% from a year prior.
  • EBITDA Margin came in at 2886419.34% for Q4 2022, down from 33364.36% in the prior quarter.
  • The five-year high for EBITDA Margin was 644.49% in Q3 2020, with the low at 2886419.34% in Q4 2022.
  • Historically, EBITDA Margin has averaged 268262.7% across 3 years, with a median of 1771.06% in 2021.
  • Biggest five-year swings in EBITDA Margin: plummeted -46010bps in 2021 and later crashed -288070777bps in 2022.
  • Year by year, EBITDA Margin stood at 877.48% in 2020, then tumbled by -551bps to 5711.57% in 2021, then plummeted by -50436bps to 2886419.34% in 2022.
  • Business Quant data shows EBITDA Margin for IMRX at 2886419.34% in Q4 2022, 33364.36% in Q3 2022, and 12223.67% in Q2 2022.